Real-World Clinical Outcomes and Prognostic Factors for Patients with Advanced Angiosarcoma who Received Systemic Treatment
Open Access
- 15 October 2021
- journal article
- research article
- Published by Korean Cancer Association in Cancer Research and Treatment
- Vol. 53 (4), 1195-1203
- https://doi.org/10.4143/crt.2020.1337
Abstract
PurposeAngiosarcoma is a highly aggressive mesenchymal tumor. Although systemic chemotherapy is often considered for the inoperable or metastatic angiosarcoma, the outcome of such treatment is unsatisfactory and poorly delineated. Materials and MethodsWe reviewed electronic medical records of 75 patients with angiosarcoma who were treated with systemic chemotherapy for inoperable or metastatic disease. Patients were classified as having liver involvement if they had either primary or metastatic hepatic lesions. ResultsAmong the patients evaluated, 51 patients were male (68%) and 24 patients (32%) had primary cutaneous angiosarcoma. Liver involvement was present in 28 patients (37.3%). A total of 59 patients received first-line weekly paclitaxel (wPac) and showed an objective response rate (ORR) of 23.7% (n=14), a median progression free survival (mPFS) of 4.0 months (95% confidence interval [CI] 3.0–6.1), and a median overall survival (mOS) of 10.2 months (95% CI 7.0–14.6). Among patients without liver involvement, patients receiving wPac (n=35) had significantly prolonged mPFS (5.8 vs. 3.2 months, respectively, p=0.014) with a tendency for prolonged mOS (13.8 vs. 11.6 months, respectively, p=0.13) than those receiving other regimens (n=12). A total of 24 patients received second- or later-line pazopanib monotherapy and showed an ORR of 16.7% (n=4), a mPFS of 2.4 months (95% CI 1.8–4.3) and a mOS of 5.4 months (95% CI 3.5–NA). ConclusionTreatment with first-line wPac and later-line pazopanib seems to provide survival benefit, especially for patients with advanced angiosarcoma without liver involvement.Keywords
This publication has 28 references indexed in Scilit:
- The pharmacological bases of the antiangiogenic activity of paclitaxelAngiogenesis, 2013
- Angiosarcoma: State of the art and perspectivesCritical Reviews in Oncology/Hematology, 2011
- Pazopanib: Clinical development of a potent anti-angiogenic drugCritical Reviews in Oncology/Hematology, 2011
- AngiosarcomaThe Lancet Oncology, 2010
- AngiosarcomaAnnals of Surgery, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Acute liver failure due to primary angiosarcoma: A case report and review of literatureWorld Journal of Surgical Oncology, 2008
- Hepatic angiosarcoma manifested as recurrent hemoperitoneumWorld Journal of Gastroenterology, 2008
- Treatment and Outcome of 82 Patients with AngiosarcomaAnnals of Surgical Oncology, 2007
- MDM-2 Oncoprotein Overexpression, p53 Gene Mutation, and VEGF Up-Regulation in AngiosarcomasThe American Journal of Pathology, 1998